William Blair Has Negative Outlook for LRMR Q1 Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Stock analysts at William Blair cut their Q1 2025 earnings per share (EPS) estimates for shares of Larimar Therapeutics in a research report issued to clients and investors on Monday, March 24th. William Blair analyst M. Minter now forecasts that the company will post earnings per share of ($0.46) for the quarter, down from their prior estimate of ($0.35). The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. William Blair also issued estimates for Larimar Therapeutics’ Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.01) EPS, Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.52) EPS, Q4 2026 earnings at ($0.52) EPS and FY2026 earnings at ($2.07) EPS.

Larimar Therapeutics (NASDAQ:LRMR) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.16).

LRMR has been the subject of a number of other research reports. HC Wainwright lifted their price objective on Larimar Therapeutics from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Tuesday. Truist Financial began coverage on Larimar Therapeutics in a report on Wednesday, January 29th. They set a “buy” rating and a $18.00 price target for the company. Robert W. Baird lowered their price target on Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating for the company in a research note on Tuesday. Finally, Guggenheim reaffirmed a “buy” rating and set a $26.00 price objective on shares of Larimar Therapeutics in a research report on Tuesday. Eleven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $20.22.

Larimar Therapeutics Stock Down 2.1 %

Larimar Therapeutics stock opened at $2.35 on Thursday. Larimar Therapeutics has a 12 month low of $2.19 and a 12 month high of $11.20. The stock has a market cap of $149.95 million, a P/E ratio of -2.04 and a beta of 0.99. The company’s fifty day simple moving average is $3.08 and its 200-day simple moving average is $5.12.

Institutional Investors Weigh In On Larimar Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC lifted its stake in shares of Larimar Therapeutics by 15.7% in the fourth quarter. Janus Henderson Group PLC now owns 6,443,286 shares of the company’s stock worth $24,936,000 after buying an additional 876,431 shares during the last quarter. Blue Owl Capital Holdings LP raised its holdings in Larimar Therapeutics by 11.7% in the 4th quarter. Blue Owl Capital Holdings LP now owns 4,653,040 shares of the company’s stock worth $18,007,000 after acquiring an additional 486,211 shares during the period. Adage Capital Partners GP L.L.C. lifted its position in Larimar Therapeutics by 23.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,100,000 shares of the company’s stock worth $8,127,000 after acquiring an additional 399,123 shares during the last quarter. Alyeska Investment Group L.P. lifted its position in Larimar Therapeutics by 38.6% during the 4th quarter. Alyeska Investment Group L.P. now owns 984,077 shares of the company’s stock worth $3,808,000 after acquiring an additional 273,920 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Larimar Therapeutics by 45.1% during the fourth quarter. Renaissance Technologies LLC now owns 513,542 shares of the company’s stock valued at $1,987,000 after acquiring an additional 159,700 shares during the period. Institutional investors own 91.92% of the company’s stock.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.